KR20260027358A - Anca 연관 혈관염에 대한 c5a 길항제의 투여 및 효과 - Google Patents

Anca 연관 혈관염에 대한 c5a 길항제의 투여 및 효과

Info

Publication number
KR20260027358A
KR20260027358A KR1020267004102A KR20267004102A KR20260027358A KR 20260027358 A KR20260027358 A KR 20260027358A KR 1020267004102 A KR1020267004102 A KR 1020267004102A KR 20267004102 A KR20267004102 A KR 20267004102A KR 20260027358 A KR20260027358 A KR 20260027358A
Authority
KR
South Korea
Prior art keywords
treatment
level
complement factor
administering
abacopan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020267004102A
Other languages
English (en)
Korean (ko)
Inventor
준 뎅
페트루스 베커
잔 힐슨
Original Assignee
케모센트릭스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 케모센트릭스, 인크. filed Critical 케모센트릭스, 인크.
Publication of KR20260027358A publication Critical patent/KR20260027358A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020267004102A 2018-06-07 2019-06-06 Anca 연관 혈관염에 대한 c5a 길항제의 투여 및 효과 Pending KR20260027358A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862682013P 2018-06-07 2018-06-07
US62/682,013 2018-06-07
KR1020217000253A KR20210018906A (ko) 2018-06-07 2019-06-06 Anca 연관 혈관염에 대한 c5a 길항제의 투여 및 효과
PCT/US2019/035758 WO2019236820A1 (en) 2018-06-07 2019-06-06 Dosing and effect of c5a antagonist with anca-associated vasculitis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217000253A Division KR20210018906A (ko) 2018-06-07 2019-06-06 Anca 연관 혈관염에 대한 c5a 길항제의 투여 및 효과

Publications (1)

Publication Number Publication Date
KR20260027358A true KR20260027358A (ko) 2026-02-27

Family

ID=68764799

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020267004102A Pending KR20260027358A (ko) 2018-06-07 2019-06-06 Anca 연관 혈관염에 대한 c5a 길항제의 투여 및 효과
KR1020217000253A Ceased KR20210018906A (ko) 2018-06-07 2019-06-06 Anca 연관 혈관염에 대한 c5a 길항제의 투여 및 효과

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217000253A Ceased KR20210018906A (ko) 2018-06-07 2019-06-06 Anca 연관 혈관염에 대한 c5a 길항제의 투여 및 효과

Country Status (15)

Country Link
US (2) US11191756B2 (https=)
EP (1) EP3801519A4 (https=)
JP (2) JP2021527062A (https=)
KR (2) KR20260027358A (https=)
CN (1) CN112423752A (https=)
AU (1) AU2019282327B2 (https=)
BR (1) BR112020024842A2 (https=)
CA (1) CA3102403A1 (https=)
CL (1) CL2020003171A1 (https=)
IL (1) IL279188B2 (https=)
MA (1) MA52808A (https=)
MX (1) MX2020013166A (https=)
SG (1) SG11202011961YA (https=)
WO (1) WO2019236820A1 (https=)
ZA (1) ZA202007615B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11191756B2 (en) 2018-06-07 2021-12-07 Chemocentryx, Inc. Dosing and effect of C5a antagonist with ANCA-associated vasculitis
WO2020112961A1 (en) 2018-11-30 2020-06-04 Chemocentryx, Inc. Capsule formulations
CN114867473A (zh) * 2019-11-08 2022-08-05 凯莫森特里克斯股份有限公司 补体成分c5a受体的盐形式
US11603356B2 (en) 2019-11-08 2023-03-14 Chemocentryx, Inc. Amorphous form of a complement component C5a receptor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1739078A1 (de) * 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
US20080188528A1 (en) 2006-12-22 2008-08-07 Biediger Ronald J Modulators of C3a receptor and methods of use thereof
RU2010138612A (ru) * 2008-02-20 2012-03-27 Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR
RS54998B1 (sr) * 2008-12-22 2016-11-30 Chemocentryx Inc Antagonisti c5ar
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
RS56332B1 (sr) 2010-06-24 2017-12-29 Chemocentryx Inc Antagonisti c5ar
DK3200791T3 (da) 2014-09-29 2020-05-25 Chemocentryx Inc Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister
WO2016166357A2 (en) 2015-04-17 2016-10-20 The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth, Near Dublin Method and assay for diagnosing rapidly progressive glomerulonephritis in a subject
EP3439658B1 (en) 2016-04-04 2021-11-24 ChemoCentryx, Inc. Soluble c5ar antagonists
CA3078732A1 (en) 2017-10-31 2019-05-09 Chemocentryx, Inc. C5ar inhibitor reduction of urinary scd163
US11191756B2 (en) 2018-06-07 2021-12-07 Chemocentryx, Inc. Dosing and effect of C5a antagonist with ANCA-associated vasculitis

Also Published As

Publication number Publication date
ZA202007615B (en) 2024-05-30
CA3102403A1 (en) 2019-12-12
MX2020013166A (es) 2021-03-29
JP2021527062A (ja) 2021-10-11
EP3801519A1 (en) 2021-04-14
AU2019282327A1 (en) 2021-01-07
MA52808A (fr) 2021-04-14
CN112423752A (zh) 2021-02-26
US11191756B2 (en) 2021-12-07
CL2020003171A1 (es) 2021-06-04
KR20210018906A (ko) 2021-02-18
AU2019282327B2 (en) 2025-04-24
EP3801519A4 (en) 2022-03-30
SG11202011961YA (en) 2020-12-30
US12350263B2 (en) 2025-07-08
WO2019236820A1 (en) 2019-12-12
IL279188B2 (en) 2026-04-01
US20220296576A1 (en) 2022-09-22
IL279188A (en) 2021-01-31
BR112020024842A2 (pt) 2021-03-02
US20190374524A1 (en) 2019-12-12
IL279188B1 (en) 2025-12-01
JP2024114706A (ja) 2024-08-23

Similar Documents

Publication Publication Date Title
US12350263B2 (en) Dosing and effect of C5a antagonist with ANCA-associated vasculitis
US11779576B2 (en) Method of treating C3 glomerulopathy
Zhang et al. Doxycycline alleviates paraquat-induced acute lung injury by inhibiting neutrophil-derived matrix metalloproteinase 9
JP6462045B2 (ja) スルフォラファンの単離及び精製
JP2018514540A (ja) 点頭てんかん治療へのカンナビジオールの使用
KR20180024010A (ko) 동결건조된 약제학적 조성물
JP2023500919A (ja) 関節炎の処置
CN104224772A (zh) 一种包含丁苯酞和冰片的药物组合物及其应用
CN110325182A (zh) 使用多能抗炎和代谢调节剂治疗炎症相关病症的方法
BR112019020451A2 (pt) composições e métodos para se direcionar e matar células-tronco positivas de câncer ?lfa-v beta-3 positiva (cscs) e tratamento de cânceres resistentes ao medicamento
EP4676458A1 (en) Use of myriocin as adjuvant in glaucoma surgery
MXPA04011794A (es) Composiciones para uso terapeutico que comprenden una vitamina, una sal de metal e insulina o una hormona de crecimiento.
RU2835509C2 (ru) Дозирование и эффект c5a антагониста при anca-ассоциированном васкулите
JP6051315B2 (ja) 乾癬を処置するためのピドチモドの使用
KR20130040825A (ko) 과황산화 글루코피라노사이드
AU2015321365A1 (en) A combination of kynurenine and antigen presenting cells (APC) as therapeutics and methods for their use in immune modulation
CN107106566A (zh) 晶状体硬化抑制剂
ES2932076T3 (es) Moduladores agonistas de los receptores de glucocorticoides selectivos (SEGRAM) no esteroideos y usos de los mismos
KR20190109192A (ko) 푸니칼라진을 포함하는 par2 활성 억제용 조성물
JP2026513467A (ja) ヒドロキシピロロンの免疫学
JP2002363076A (ja) フマギロール誘導体を用いる腫瘍の治療方法
CN101432000A (zh) 用于变应性眼病或变应性鼻病的包含三环性三唑并苯并氮杂衍生物的预防剂或治疗剂
KR20260023197A (ko) 세사민을 포함하는 아토피성 피부염의 개선 또는 치료용 조성물
US20220265574A1 (en) Methods of using cannabidiol and a steroid
Kale et al. Therapeutics for Allergy Management

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)